Complete response (CR) and partial response (PR)
A complete response means every measurable trace of the cancer has disappeared on scans or in the marrow; a partial response means it has shrunk by at least 30% (RECIST) but is still there. Neither is the same as cure: microscopic disease can remain.
Solid tumour responses are defined by RECIST 1.1 (complete: all target lesions gone and nodes <10 mm; partial: ≥30% decrease in summed diameters; progressive: ≥20% increase or new lesions; stable: neither); lymphoma uses Lugano and PET; leukaemia uses marrow blast count and count recovery (CR, CRi for incomplete recovery); myeloma uses IMWG (stringent CR, VGPR, PR). Complete responses are the strongest single-arm signal and, when durable, drive accelerated approvals; the proportion of complete responders and the depth of response (MRD, ctDNA clearance) increasingly predict long-term outcome. In neoadjuvant settings pathological complete response is judged on the resected specimen, and clinical complete response guides organ preservation.
Pages like this
not linked directly; found by shared links- TermFlow cytometry (immunophenotyping)
Shares Blasts (leukaemic blast cells), Undetectable MRD (uMRD / MRD-negative).
- TermComplete response
Shares RECIST, Pathologic complete response (pCR), Objective response rate (ORR).
- TermSingle-arm trial
Shares Duration of response (DoR) and disease control rate (DCR), Objective response rate (ORR).
- TermMaintenance therapy
Shares Induction therapy, Undetectable MRD (uMRD / MRD-negative).
- TermBlinded independent central review (BICR)
Shares RECIST, Objective response rate (ORR).
- TermDe-escalation, escalation and response-adapted therapy
Shares Deauville score and PET-adapted therapy, Undetectable MRD (uMRD / MRD-negative).
- TermPartial response
Shares RECIST, Objective response rate (ORR).
- TermSurrogate endpoint
Shares Pathologic complete response (pCR), Objective response rate (ORR).